Overview

A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already available to treat Rheumatoid Arthritis) when added to treatment with methotrexate. The purpose of this study is also to find out which dose of AZD5672 is the most effective at treating RA and to find out how well the body tolerates AZD5672 when taken for up to 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Etanercept
N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide